ADAM17 and nonpapillary renal cell carcinoma: Overall, these findings define a novel ERβ/circAHNAK/FMR1/ADAM17 axis that integrates USP10‐mediated deubiquitination with FMR1‐mediated m6A modification to promote ADAM17 expression and angiogenesis in ccRCC.